Penumbra, Inc. Common Stock (NY:PEN)

317.55 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Penumbra, Inc. Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Penumbra Introduces Next Generation REAL® y-Series™, Expanding Virtual Reality Healthcare Platform

March 31, 2022

From Penumbra, Inc

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2022 ↗

March 08, 2022

Upgrades According to Janney Montgomery Scott, the prior rating for Wintrust Financial Corp (NASDAQ:WTFC) was changed from Neutral to Buy. Wintrust Finl earned $1.58 in the fourth...

Via Benzinga

Recap: Penumbra Q4 Earnings ↗

February 22, 2022

Penumbra (NYSE:PEN) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Penumbra...

Via Benzinga

Penumbra Posts Mixed Bag Q4 Results, Reports Topline Growth Of 22% ↗

February 23, 2022

Penumbra Inc (NYSE: PEN) posted Q4 FY21 revenue of $204 million, +22.2% Y/Y (up 23% in constant currency), beating the consensus of $194.30 million. Revenue from sales...

Via Benzinga

Penumbra's Return on Invested Capital Insights ↗

February 23, 2022

Benzinga Pro data, Penumbra (NYSE:PEN) reported Q4 sales of $204.01 million. Earnings fell to a loss of $24.63 million, resulting in a 406.72% decrease from last quarter. In Q3,...

Via Benzinga

Earnings Scheduled For February 22, 2022 ↗

February 22, 2022

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report quarterly earnings at $0.13 per share on revenue of $439.63 million. • Sohu...

Via Benzinga

Earnings Outlook For Penumbra ↗

February 21, 2022

Penumbra (NYSE:PEN) is set to give its latest quarterly earnings report on Tuesday, 2022-02-22. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Penumbra Weighs Combination With Shockwave Medical: Bloomberg ↗

January 10, 2022

Penumbra Inc (NYSE: PEN) is exploring a potential deal with Shockwave Medical Inc (NASDAQ: SWAV), Bloomberg reported citing people with knowledge of the...

Via Benzinga

CEO Of Penumbra Trades $3.9M In Company Stock ↗

November 16, 2021

Adam Elsesser, CEO at Penumbra (NYSE:PEN), made a large buy and sell of company shares on November 11, according to a new SEC filing. What Happened: A Form 4 filing from the U.S....

Via Benzinga

Topics Regulatory Compliance

Penumbra's Thrombectomy System Shows Safety, Clinical Benefit ↗

November 05, 2021

Penumbra Inc (NYSE: PEN) announced that the CHEETAH clinical study of its Indigo System CAT RX Catheter met the primary endpoint. As part of the Indigo Aspiration...

Via Benzinga

Penumbra: Q2 Earnings Insights ↗

August 09, 2021

Shares of Penumbra (NYSE:PEN) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 170.00% over the past year to $0....

Via Benzinga

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

New Data Demonstrates Safety and Performance of Continuous Aspiration Thrombectomy with Penumbra’s Indigo® System CAT™ RX Catheter in High-Risk Patients with Acute Coronary Syndrome

November 05, 2021

From Penumbra, Inc.

Via Business Wire

Penumbra, Inc (PEN) Q3 2021 Earnings Call Transcript ↗

November 03, 2021

PEN earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering ↗

November 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...

Via Benzinga

Topics Retirement

Notable Penumbra Insider Trades $3.8M In Company Stock ↗

October 14, 2021

Adam Elsesser, CEO And President at Penumbra (NYSE:PEN), made a large buy and sell of company shares on October 11, according to a new SEC filing. What Happened: A Form 4 filing...

Via Benzinga

Topics Regulatory Compliance

Earnings Scheduled For November 3, 2021 ↗

November 03, 2021

Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion....

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

CEO And President Of Penumbra Trades $4.18 Million In Company Stock ↗

September 16, 2021

Adam Elsesser, CEO And President at Penumbra (NYSE:PEN), made a large buy and sell of company shares on September 13, according to a new SEC filing. What Happened: A Form 4 filing...

Via Benzinga

Topics Regulatory Compliance

Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2021 ↗

September 16, 2021

Upgrades For Signet Jewelers Ltd (NYSE:

Via Benzinga

Penumbra Stock Registers A Healthy RS Rating ↗

September 15, 2021

Penumbra shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81.

Via Investor's Business Daily

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Penumbra, Inc. Investors With Losses to Inquire About Class Action Investigation – PEN

August 27, 2021

From The Rosen Law Firm, P.A.

Via Business Wire

Penumbra Q2 Earnings Beat Estimates; Raises FY21 Sales Outlook ↗

August 10, 2021

Penumbra Inc (NYSE: PEN) reported Q2 sales of $184.3 million, an increase of 75.3% Y/Y, or 72.7% on a constant currency basis, beating the consensus of $170.76 million...

Via Benzinga

Topics Earnings

Penumbra Introduces REAL® i-Series™, Expanding REAL Immersive System to Support Broad Range of Care Providers and Mental Health Professionals

August 10, 2021

From Penumbra, Inc.

Via Business Wire

Penumbra, inc (PEN) Q2 2021 Earnings Call Transcript ↗

August 09, 2021

PEN earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Penumbra Receives FDA Clearance for RED 62 Reperfusion Catheter, Enabling Physicians to Address Broad Range of Stroke Patients

June 23, 2021

From Penumbra, Inc.

Via Business Wire

Earnings Scheduled For August 9, 2021 ↗

August 09, 2021

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 4, 2021 ↗

June 04, 2021

Upgrades According to Argus Research, the prior rating for Diageo PLC (NYSE:DEO) was changed from Hold to Buy. The current stock performance of Diageo shows a 52-week-high...

Via Benzinga

NYSE: PEN Long Term Investor Notice: Investigation of Potential Wrongdoing at Penumbra, Inc. ↗

May 10, 2021

San Diego, CA -- (SBWIRE) -- 05/10/2021 -- An investigation on behalf of current long term investors in Penumbra, Inc. (NYSE: PEN) shares over possible breaches of fiduciary duty by certain officers...

Via SBWire

Topics Death Lawsuit

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.